FDA — authorised 27 February 1970
- Application: NDA016774
- Marketing authorisation holder: NOVARTIS
- Local brand name: SERENTIL
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 MESORIDAZINE BESYLATE in United States
FDA authorised MESORIDAZINE BESYLATE on 27 February 1970
Marketing authorisations
FDA — authorised 27 February 1970
- Application: NDA016775
- Marketing authorisation holder: NOVARTIS
- Local brand name: SERENTIL
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Status: approved
MESORIDAZINE BESYLATE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in United States
Frequently asked questions
Is MESORIDAZINE BESYLATE approved in United States?
Yes. FDA authorised it on 27 February 1970; FDA authorised it on 27 February 1970; FDA has authorised it.
Who is the marketing authorisation holder for MESORIDAZINE BESYLATE in United States?
NOVARTIS holds the US marketing authorisation.